Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets

Abstract

Adherence and persistence improved significantly after switching from DFX-DT to DFX-FCT for all diseases, but especially MDS.

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

“…Compliance (~ 90% mean relative consumed tablet count) and persistence (95-100%) rates with deferasirox FCT during this study were found to be on the higher side. Persistence rates (proportion of patients with continuous use of deferasirox FCT with no interruption for ≥ 30 days or ≥ 60 days) in this study are comparable to the real-world data on persistence in patients who switched from deferasirox DT (39-80%) to deferasirox FCT (60-96%) [1].…”

“…Iron overload in chronic anemias represents a serious consequence of impaired hematopoiesis and repeated blood transfusions leading to end-organ damage, reduced quality of life, and decreased survival. Iron chelation therapy (ICT) can be a life-long requirement in chronic transfusion-dependent refractory anemias, including β-thalassemia, sickle-cell disease, and myelodysplastic syndrome (MDS) [1,2]. Despite the proven benefit of ICT, patient compliance to long-term ICT is challenging [3].…”

“…Currently, there are no direct comparison studies for the 2 oral chelators; however, once-daily simpler use of deferasirox has been projected to be a more cost-effective option than the thrice-daily administration of oral deferiprone in the management of long-term complications [ 7 , 10 ]. The deferasirox film-coated tablet (FCT) formulation, with a simpler oral administration and improved palatability and gastrointestinal (GI) tolerability compared with deferasirox DT, offers a better option for optimal patient acceptance and improved compliance to long-term therapy [ 1 , 11 ]. Thus, an appropriate choice of ICT plays an important role in patient compliance to chelation therapy.…”

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)

“…DFX is available in several forms, including Exjade® dispersible tablets (DFX-DT, oral administration once-daily, completely dissolved in liquids and consumed 30 min before meals on an empty stomach), Jadenu® granule formulation of DFX (DFX-GF),[ 8 ] and Nanojade® a new film-coated tablets formulation of DFX (DFX-FCT) in Iran pharmaceutical market. Nanojade® is a generic drug from Jadenu® (Novartis).…”

“…Furthermore, improved palatability and compliancy, high bioavailability, and low gastrointestinal side effects promise a better treatment with Jadenu® for a long time. [ 8 11 ] DFX-FCT is prescribed based on body weight and has three dose strengths and is available in three dose strengths (90 mg, 180, and 360 mg). [ 11 ]…”